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Abstract
Background: As a promising way to transform medicine, mass spectrometry based proteomics technologies have
seen a great progress in identifying disease biomarkers for clinical diagnosis and prognosis. However, there is a lack
of effective feature selection methods that are able to capture essential data behaviors to achieve clinical level
disease diagnosis. Moreover, it faces a challenge from data reproducibility, which means that no two independent
studies have been found to produce same proteomic patterns. Such reproducibility issue causes the identified
biomarker patterns to lose repeatability and prevents it from real clinical usage.
Methods: In this work, we propose a novel machine-learning algorithm: derivative component analysis (DCA) for
high-dimensional mass spectral proteomic profiles. As an implicit feature selection algorithm, derivative component
analysis examines input proteomics data in a multi-resolution approach by seeking its derivatives to capture latent
data characteristics and conduct de-noising. We further demonstrate DCA’s advantages in disease diagnosis by
viewing input proteomics data as a profile biomarker via integrating it with support vector machines to tackle the
reproducibility issue, besides comparing it with state-of-the-art peers.
Results: Our results show that high-dimensional proteomics data are actually linearly separable under proposed
derivative component analysis (DCA). As a novel multi-resolution feature selection algorithm, DCA not only
overcomes the weakness of the traditional methods in subtle data behavior discovery, but also suggests an
effective resolution to overcoming proteomics data’s reproducibility problem and provides new techniques and
insights in translational bioinformatics and machine learning. The DCA-based profile biomarker diagnosis makes
clinical level diagnostic performances reproducible across different proteomic data, which is more robust and
systematic than the existing biomarker discovery based diagnosis.
Conclusions: Our findings demonstrate the feasibility and power of the proposed DCA-based profile biomarker
diagnosis in achieving high sensitivity and conquering the data reproducibility issue in serum proteomics.
Furthermore, our proposed derivative component analysis suggests the subtle data characteristics gleaning and de-
noising are essential in separating true signals from red herrings for high-dimensional proteomic profiles, which
can be more important than the conventional feature selection or dimension reduction. In particular, our profile
biomarker diagnosis can be generalized to other omics data for derivative component analysis (DCA)’s nature of
generic data analysis.
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Background
With the surge in serum proteomics, large volumes of
mass spectral serum proteomic data are available to
make molecular diagnosis of complex disease pheno-
types possible. As a promising way to revolutionize
medicine, serum proteomics demonstrates a great
potential in identifying novel biomarker patterns from
the serum proteome for diagnosis, prognosis, and early
disease discovery [1-3]. However, high-performance dis-
ease phenotype discrimination remains a challenge in
translational bioinformatics due to special characteristics
of serum proteomics data, in addition to its well-known
data reproducibility issue, which means that no two
independent studies have been found to produce same
proteomic patterns [3-5].
A serum proteomic data set can be represented as a
matrix X ∈ n×p after preprocessing, where each row
represents protein expression at a mass-to-charge (m/z)
ratio of peptides or proteins and each column represents
protein expression from a sample/observation (e.g., a
control or cancer subject) across all m/z ratios in experi-
ment. The number of rows is much greater than the
number of columns, p << n, that is #variables (peptides/
proteins) is much greater than #samples. Usually
n∼O(104), and p∼O(102). Although there are a large
amount of m/z ratios (peptides or proteins), only a few
numbers of them (e.g., peaks) have meaningful contribu-
tion to disease diagnosis and data variations. Moreover,
such data are not noise-free because normalization meth-
ods cannot remove built-in systems noise from mass
spectrometry technology itself [6,7]. In particular, the
high-dimensionality directly prevents conventional classi-
fication algorithms from achieving clinical rivaling dis-
ease diagnosis, limits its generalization capability or even
causes some regularity problem in classification [7].
Quite a lot feature selection methods have been
employed in serum proteomic data classification to glean
informative features, reduce dimension, or conduct de-
noising in order to achieve high accuracy disease diagnosis
[7-10]. It is noted that a feature refers to a row in a serum
proteomic data set, which are biologically peptides or pro-
teins. In this work, we categorize them into input-space
and subspace methods respectively. The former seeks a
feature subset X′ ∈ m×p,m << n in the same space n×p
as input data X by conducting a hypothesis test (e.g.,
t-test), or wrapping a classifier to features recursively; The
latter conducts dimension reduction by transforming
data X into a subspace S induced by a linear or nonlinear
transformation f : X → S where S = span(s1, s2 . . . sk),
k ≤ p ≤ n, k ≤ p ≤ n, and seeking meaningful linear com-
binations of features. For example, the subspace spanned
by all principal components when the transformation is
induced by principal component analysis (PCA) [11].
All subspace methods can be formulated as a matrix
decomposition problem: X∼SPT ,S ∈ n×k,P ∈ p×k where
different methods construct different basis matrices S and
different feature matrices P according to different termina-
tion conditions. For instance, nonnegative matrix factori-
zation (NMF) seeks nonnegative matrix decomposition
such that ||X∼SPT || is minimized under an Euclidean dis-
tance or K-L divergence [12,13]. In fact, almost all PCA,
ICA, and NMF ‘s extensions such as nonnegative principal
component analysis (NPCA), sparse NMF, and other
methods such as random projection methods all fall into
this category [8,12-16].
However, these methods may not always contribute to
improving diagnosis in serum proteomics robustly.
Instead, it was reported that classifiers integrated with
them may usually demonstrate large oscillations in per-
formance for different data sets and some even got
worse performance than the case without feature selec-
tion [7,8,10]. Moreover, there was no systematic work
on addressing the limitations of those feature selection
methods. In this work, we address these methods’ lim-
itations before introducing our novel derivative compo-
nent analysis (DCA).
Lack of de-noising schemes
The input-space methods usually lack de-noising
schemes and assume input data is clean or nearly clean.
Such an assumption can be true for the data that are by
nature clean or with quite low-level noise (e.g., financial
data). However, it appears to be inappropriate for serum
proteomics data since they usually contain nonlinear
noise from profiling systems, and technical/biological
artifacts. The noise would enter feature selection as out-
liers and produce less informative or even ad-hoc fea-
ture sets (e.g., peaks with less biological meaning),
which would lead to an inaccurate or even poor decision
function in classification and affect the disease pheno-
type diagnosis, generalization, and biomarker discovery
in translational bioinformatics.
Latent data characteristics missing
Those subspace methods have difficulties in capturing
subtle or latent data characteristics, because subspace
methods transform data into another subspace to seek
meaningful feature combination and original spatial
coordinates are ‘lost’, which makes it almost impossible
to track those features contributing to the behaviors. The
latent data characteristics refer to subtle data behaviors
interpreting transient data changes (we use words ‘subtle’
and ‘latent’ equivalently when describing data character-
istics in our context). Quite different from global data
characteristics that referring to the holistic data behaviors
interpreting long-time interval data changes, subtle data
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characteristics have to be represented by the first or even
high-level derivative of data mathematically [8,10].
We use principal component analysis (PCA) as an
example to address this issue. Given input data with zero
mean X ∈ n×p, the subspace is spanned by selected PCs,
i.e. S = span(u1, u2, . . . uk)1 ≤ k ≤ p. Since each subspace
basis (PC) receives contributions from all features (pep-
tides/proteins) in the linear combinations, changes in one
feature will inevitably affect all bases globally. Although
it is biologically important to identity which protein/
peptide has more contributions to the data change, it is
quite hard to achieve it because their coefficients in the
linear combination are not usually comparable [6].
Moreover, subspace basis calculation does not involve
the feature derivative information or its related approxi-
mation, which causes each PC not to be able to capture
latent (subtle) data characteristics well. As such, only glo-
bal data characteristics can be captured well and subtle
data characteristics, which are essential in achieving high
performance diagnosis, may be totally missed. For exam-
ple, some malignant and benign tumors may have similar
global data characteristics but different subtle data char-
acteristics in serum profiling. As such, detecting subtle
data characteristics is essential to achieve a clinical level
diagnosis.
Although various subspace methods such as sparse-
PCA, nonnegative-PCA, and sparse-NMF [12,8,14,16],
have been proposed to enhance subtle data characteristics
capturing by imposing non-negativity or sparsity con-
straints in order to seek subspace bases through solving a
nonlinear optimization problem, they are usually charac-
terized by high complexities (e.g., nonnegative PCA [6,8])
and none of them seems to be able to catch subtle data
characteristics by examining the features ‘beyond’ their
original data level.
In this work, we propose a de novo derivative compo-
nent analysis (DCA), which evolves from author’s pre-
vious work in gene and protein expression omics data
analysis [8,9], to overcome the current feature selection
methods’ weaknesses for the sake of clinical level disease
diagnosis in serum proteomics. It is worthwhile to point
out that our DCA is a novel machine learning algorithm
based on our global and local feature selection theory
proposed in [8], which is more complicated and power-
ful than the serum proteomics data analysis methods
that straight-forwardly apply wavelet transforms to a
proteomic sample and conduct classic statistical tests to
following wavelet coefficients [17]. Our DCA employs
discrete wavelet transforms (DWT) [18] to look at
serum proteomics data in ’multiple windows’ to extract
latent data characteristics and achieve de-noising by
retrieving ‘data derivatives’.
Furthermore, we employ benchmark serum proteomic
data to demonstrate DCA’s superiority in disease diagnosis
by proposing a novel diagnosis algorithm DCA-SVM and
comparing it with the other state-of-the-art peers. The
exceptional performance of our DCA-SVM suggests it can
be a potential way to overcome the serum proteomics’
reproducibility by viewing input data as a profile biomar-
ker. As a key result in this work, we present DCA-MARK,
a DCA-based biomarker discovery algorithm that strongly
demonstrates high-dimensional serum proteomics data’s
linear separability, which not only has an important mean-
ing in machine learning, but also has practical impacts on
translational bioinformatics for its novelty. To the best of
our knowledge, it is the first work that is able to linearly
separate high-dimensional serum proteomic data with few
biomarkers.
Derivative Component Analysis (DCA)
Different from its conventional definition, a feature is no
longer viewed as an indecomposable information unit in
DCA. Instead, all features are hierarchically decomposed
into different components to discover data derivatives to
capture subtle data characteristics and conduct de-nois-
ing. The proposed derivative component analysis (DCA)
consists of the following three steps.
First, a discrete wavelet transform (DWT) is applied to
all features to decompose it hierarchically as a set of
detail coefficient matrices cD1, cD2 . . . cDJ and an
approximation matrix cAJ under a transform level J.
Since DWT is done on a set of dyadic grid points hier-
archically, the dimensionalities of the approximation and
detail coefficient matrices shrink dyadically from level 1
to level J [17]. For example, given a proteomic data set
with 10 samples across 1024 m/z ratios under a DWT
with a transform level J = 5, cD1 is a 10 × 512 matrix
and cD2 is 10 × 256 matrix. Similarly, cD5 and cA5 both
are 10 × 32 matrices.
The approximation matrix and coarse level detail coeffi-
cient matrices (e.g., cDJ) capture the global data character-
istics, because they contain contributions from the
features disclose slow changes in ‘long-time windows’, if
we view each m/z ratio as a corresponding time point in
our context. Similarly, the fine level detail coefficient
matrices (e.g., cD1, cD2), capture subtle data characteris-
tics, because they contain contributions from the features
that disclose quick changes in ‘short-time windows’. In
fact, the fine level detail matrices are components to
reflect data derivatives in different time windows. Further-
more, most system noises are hidden in these components
for its heterogeneity with respect to true signals. In sum-
mary, the first step separates global characteristics, subtle
data characteristics, and noise in different resolutions.
Second, retrieve the most important subtle data beha-
viors and remove noise by reconstructing the fine level
detail coefficient matrices before or at a presetting cutoff
level τ (e.g.,τ = 3). Such construction consist of two
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steps: 1) Conduct principal component analysis (PCA)
for the detail matrices cD1, cD2 . . . cDτ 2) Reconstruct
each detail coefficient matrix by using its first m leading
loading vectors, i.e., principal components, in its each
principal component (PC) matrix. Usually, we set m = 1,
i.e., we employ the first principal component to recon-
struct each detail coefficient matrix, which means we
only retrieve the most important subtle data characteris-
tics in detail coefficient matrix reconstruction. In fact,
the first PC based reconstruction also achieves de-nois-
ing by suppressing noise’s contribution in the detail
coefficient matrix reconstruction because noise has is
usually unlikely to appear in the 1st PC.
On the other hand, the coarse level detail coefficient
matrices after the cutoff τ: cDτ+1, cDτ+2 . . . cDJ and
approximation coefficient matrix cAJ are kept intact to
retrieve global data characteristics. In fact, parameter m
can be also determined by using a variability explanation
ratio ρm defined as follows, such that it is greater than a
threshold ρ (e.g., ρ = 60%), which is the variability expla-
nation ratio by the first principal component of those
detail coefficient matrices before or equal the cutoff.
Variability explanation ratio
Given a data set with n variables and p observations,
usually, p < n, the variability explanation ratio is the
ratio between the variance explained by the first m PCs
and the total data variances: ρm =
m∑
i=1
σi/
p∑
i=1
σi, where σj is
the variance explained by the jth PC, which is actually
the jth eigenvalue of the covariance matrix of the input
proteomic data.
It is noted that such a selective reconstruction process
in the second step extracts the most important subtle
data characteristics and conduct de-noising by suppres-
sing the contribution from system noise. This is because
only one or few principal components are employed in
reconstructing each targeted fine level coefficient matrix
cDj and those less important and noise-contained princi-
pal components are dropped in reconstruction.
Third, conduct the corresponding inverse DWT by
using the current detail and approximation coefficient
matrices to obtain an meta-data X∗ that is the corre-
sponding de-noised data set with subtle data characteris-
tics extraction and system noise removal, because of the
highlight of the most significant subtle data behaviors in
the “derivative components” based reconstructions. The
meta-data are just ‘true signals’ separated from red her-
rings that share the same dimensionality with the origi-
nal data but with less memory storage because less
important PCs are dropped in our reconstruction.
It is noted that, unlike traditional feature selection
methods, DCA is an implicit feature selection method,
where useful characteristics are selected implicitly with-
out an obvious variable removal or dimension reduction.
Algorithm 1 gives the details about DCA as follows,
where we use XT instead of X to represent input proteo-
mic data for the convenience of description, i.e. each
row is a sample and each column is a feature in the cur-
rent context.
Algorithm Derivative Component Analysis (DCA)
1. Input: XT = [x1, x2, . . . xn] xi ∈ p,DWT level J;
cutoff τ; wavelet ψ , thereshold ρ,
2. Output: Meta-data XT∗
3. Step 1. Column-wise discrete wavelet transforms
(DWT)
4. Conduct J-level DWT with wavelet ψ for each col-
umn of XT to obtain [cD1, cD2 . . . cDJ ; cAJ], cDj ∈ pj×n,
cAJ ∈ pJ×n, and pj =
[
p/2j
]
, j = 1, 2, . . . J.
5. Step 2. Derivative component analysis for latent
data characteristics extraction and de-noising
6. for j = 1 to J
7. if j ≥ τ
8. a) Do principal component analysis for each detail
matrix cDj to obtain its PC and score matrix,
9. U = [u1, u2, . . . up], ui ∈ n and S = [s1, s2 . . . spJ ],
i = 1, 2, · · · pj i = 1, 2, · · · pj
10. b) Reconstruct matrix cDj by employing first m
principal components u1, u2, . . . um, s.t. ρm ≥ p
11. cDj ← cDj × (I × IT)/pj +
m∑
i=1
ui × sTi , I = [1, 1, · · · 1]T ∈ pj
12. end if
13. end for
14. Step 3. Approximate the original data by the
inverse discrete wavelet transform
15. XT∗ ← inverseDWT([cD1, cD2 . . . cDJ; cAJ]) with the
wavelet ψ
Tuning parameters in derivative component analysis
Although an optimal DWT level can be obtained theore-
tically by following the maximum entropy principle [19],
it is reasonable to adaptively select the DWT level
J according to the ’nature’ of input data, where large
#samples corresponds to a relatively large J value, for the
convenience of computation. Although the convolution
in the DWT always introduces a few extra entries into
each feature’s corresponding detail coefficient vector in
cDj+1 such that its length is slightly more than the half
of that of in cDj [18], we have found that a large trans-
form level does not show advantages compared with the
a small transform level in feature selection. However, a
small transform level (e.g., J = 3) may bring some hard
time in separating subtle and global data characteristics
because of the limited choice for the cutoff τ. As such, we
select the DWT level as 4 ≤ J ≤ ⌈log2p
⌉
considering the
magnitude level of the #samples, i.e. p∼O(102) for a pro-
teomics data set. Correspondingly, we empirically set the
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cutoff as 1 < τ ≤ J/2 to separate the fine and coarse level
detail coefficient matrices for its robust performance.
Furthermore, we require the waveletψ in the DWT to be
orthogonal and have compact supports such as Daubechies
wavelets (e.g., ‘db8’), for the sake of the subtle data beha-
vior capturing. The variability explanation ratio threshold
is usually set as r ≥ 60%, which means the reconstructed
fine level detail coefficient matrix cDj (1 ≤ j ≤ τ) contains at
least 60% variances of the original one, to retrieve the most
important subtle data behaviors interpreted by cDj. Inter-
estingly, we have found that the first PC of each fine-level
detail coefficient matrix usually count quite a high variabil-
ity explanation ratio (e.g. >60%) for each fine-level detail
coefficient matrix cDj (1 ≤ j ≤ τ ). Thus, we relax the varia-
bility explanation ratio threshold r by only using the first
PC to reconstruct each cDj matrix to catch the subtle data
characteristics along the maximum variance direction. In
fact, we have found that using more PCs in the fine-level
detail coefficient matrix reconstruction does not demon-
strate advantages in subtle data characteristics extraction
and de-noising than using the first PC.
Figure 1 shows the meta-data of a feature obtained by
DCA on Ovarian-qaqc data with 95 controls and 121
ovarian cancer samples across 15,000 m/z ratios [20], and
its two level detail coefficient reconstructions under DCA
with τ=2, J = 7, and wavelet ’db8’. Interestingly, the meta-
data are smoother and have values in a smaller range than
the original feature for its subtle data characteristics cap-
turing and de-noising, which reflect the true expression of
the peptides/proteins at the m/z ratio better. In other
words, DCA provides a ‘zooming’ mechanism to capture
the original data’s subtle behaviors that are usually latent
in general feature selection methods. It is noted that simi-
lar results can be obtained for other mass spectral proteo-
mic profiles also.
In fact, the meta-data obtained from DCA can be viewed
as “true signals” separated from red herrings for each
serum proteomics data set. Figure 2 shows the true signals
of the 10 cancer and control samples, which are randomly
selected from Colorectal data [17] with total 48 controls
and 64 cancer samples across 16,331 m/z ratios, extracted
by our DCA under the cutoff τ=2, transform-level J = 7,
and wavelet ’db8’. For the convenience of description, true
signals are highlighted between 1,400 Da and 1,500 Da.
Interestingly, the each type of samples in the extracted
true signals appear to be smoother and more proximal to
each other besides demonstrating less variations, because
of major subtle data characteristics extraction and system
noise removal. Obviously, from a classification viewpoint,
these true signals will contribute to high accuracy diag-
noses than the original proteomic data, because the built-
in noises and redundant global data characteristics would
have a much lower chance to get involved in classification
due to derivative component analysis. Instead, subtle data
characteristics would have a greater chance of participat-
ing in the decision rule inference.
Disease diagnosis with Derivative Component Analysis
Since DCA can separate true signals from red herrings
by extracting subtle data characteristics and removing
Figure 1 A feature in Ovarian-qaqc data and its meta-data computed from DCA. The detail coefficients cD1,cD2 (blue color) and their first
PC reconstructions (red color) in DCA.
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built-in noises, it is natural to combine DCA with the
start-of-the-art classifiers to demonstrate its effective-
ness in serum proteomic disease diagnosis. We choose
support vector machines (SVM) for its efficiency and
popularity in translational bioinformatics [21]. As such,
we propose novel derivative component analysis based
support vector machines (DCA-SVM) to handle serum
proteomic disease diagnosis, which is equivalent to a
binary or multi-class classification problem. Thus, we
briefly describe the corresponding binary and multiclass
DCA-SVM as follows.
Given a binary type training samples X = [x1, x2, · · · xp]T
and their labels {xi, ci}pi=1, ci ∈ {−1, 1} its corresponding
meta-data Y = [y1, y2, · · · yp]T are computed by using
DCA, Then, a maximum-margin hyperplane:
Oh : wTy + b = 0 in n is constructed to separate the ‘+1’
(’cancer’) and ‘-1’ (’control’) types of the samples in the
meta-data Y, which is equivalent to solving the following
quadratic programming problem (standard SVM, i.e.,
C-SVM):
min
w,b,ξ
1
2
||w||22 + C
∑p
i=1
ξi
s..t. ci(wTyi + b) ≥ 1 − ξi, = 1, 2 . . . p
ξi ≥ 0
(1)
The C-SVM can be solved by seeking the solutions to
the variables α1 of the following Lagrangian dual problem,
maxα
∑p
i=1
αi − 12
∑p
i=1
∑p
j=1
αiαjcicjy
T
i yj
s..t.
∑p
i=1
αici = 0, 0 ≤ αi ≤ Ci, i = 1, 2, . . . p
ξi ≥ 0
(2)
The normal of the maximum-margin hyperplane can
be calculated by the equation s =
∑p
i=1 αiciyi, where the
sparsity of variables α1 i = 1,2,...p, makes classification
only dependent on few training points, which are few
cancerous patients or healthy subjects in the proteomics
data used for training. The decision function
f (x′) = sign(
∑p
i=1 αik(yi • y′) + b is used to determine the
class type of a testing sample x′, where y′ is its corre-
sponding meta-sample computed from DCA. The func-
tion k(yi • y′) is a kernel function mapping y and y′ into a
same-dimensional or high-dimensional feature space. In
this work, we employ the ’linear’ kernel k(x • y) = (x • y)
for its simplicity and efficiency (more detailed reason for
such a kernel selection can be found in the following sec-
tion). Such a decision function answers the query: ‘is this
proteomic sample is from a patient with a specified dis-
ease or a normal individual?’
Our multiclass DCA-SVM algorithm employs the ’one-
against-one’ for its proved advantage over the ’one-against-
all’ and ’directed acyclic SVM’ methods [21,22]. The ’one-
against-one’ method builds k(k-1)/2 binary SVM classifiers
for a data set with k classes {1,2,...k}, each of which corre-
spond to a pathological state. Each classifier is trained on
data from two classes, i.e. training samples are from the i-
th and j-th classes, i, j = 1, 2 ... k. After building all k(k-1)/2
classifiers, we employ the ’Max-wins’ voting approach to
infer its final class type: if the local decision function says
x′ is in the class i, then the class i wins one vote; Other-
wise, the class j wins one vote. Finally, sample x′ will
belong to the class with the largest vote.
The DCA-SVM ‘s advantages over SVM in disease diagnosis
It is worthwhile to point out that, compared with the
standard SVM, our DCA-SVM has a different feature
Figure 2 The true signals of 10 cancer and control samples of the Colorectal data between 1400-1500 Da.
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space due to the true-signals extraction from DCA,
which leads to a more robust decision rule than the
standard SVM (C-SVM) for inviting the de-noised data
with the subtle data characteristics in the optimal hyper-
plane construction. Obviously, the decision rule inferred
from our DCA-SVM would avoid the traditional bias
from that of the standard SVM. On the other hand, the
standard SVM’s feature space usually contains noises
from input proteomic data, and misses the subtle data
characteristics, which limit the classifier’s performance
and lead to a biased, global data characteristics favored
decision rule.
Alternatively, the DCA-SVM ‘s feature space contains
‘de-noised’ true signals with the subtle data characteris-
tics, which avoids the global data characteristics favored
decision rule inference because the subtle data charac-
teristics are also invited in SVM hyperplane construc-
tion besides the global data characteristics. As such, the
DCA-SVM can efficiently detect those samples with
similar global characteristics but different subtle charac-
teristics in disease diagnosis than the standard SVM,
which contributes to the high accuracy diagnosis.
Results
We demonstrate our DCA-SVM can achieve rivaling-
clinical diagnosis by using five benchmark high-dimen-
sional serum proteomic data sets [17,20,23-25] and
compare it with state-of-the-art peers on these data. We
introduce details about the data sets as follows.
Data sets
The benchmark data sets used in the experiment are het-
erogeneous data generated from different experiments via
different high-resolution serum profiling technologies
such as MALDI (matrix-assisted laser desorption)-TOF
(time-of-flight), SELDI (surface enhanced laser desorption
and ionization)-TOF (time-of-flight), and SELDI-QqTOF
(quadrupole time-of-flight). The details of the data sets are
as follows.
Cirrhosis data set is a three-class MALDI-TOF serum
proteomic data with total 201 spectra that consisting of
72 samples from healthy individuals, 78 samples from
patients with hepatocellular carcinoma (HCC), the most
common liver cancer, and 51 samples form cirrhosis
patients, across 23,846 m/z ratios [24]. As the major
cause of hepatocellular carcinoma, cirrhosis can be
viewed as a key intermediate stage pathologically between
a normal state and a state with hepatocellular carcinoma.
Colorectal (CRC) data set consists of 48 control and
64 cancer spectra across 16,331 m/z values [17], which
are selected from the raw data with 65, 400 m/z values
profiled by MALDI-TOF technologies to cover a range
from 0.96 to 11.16 kDa; HCC data set is a binary
SELDI-QqTOF proteomic data with total 358 spectra
that consisting of 181 controls and 176 cancers across
6,107 m/z ratios, which are selected from about 340,000
m/z values through a binning procedure for original
mass spectra [23]. As a well-known benchmark data,
Ovarian-qaqc data consist of 95 controls and 121
ovarian cancers across 15,000 m/z values, which is a
high-resolution serum proteomics data produced by
SELDI-TOF profiling [20]. Toxpath data were generated
from a toxicoproteomics experiment to conduct serum
proteomic diagnosis for doxorubicin-induced cardiotoxi-
city by Petricoin et al [25]. This data set has 115 mass
spectra consisting of 28 normal, 43 potential normal,
34 cardiotoxicities, and 10 potential cardiotoxicities,
across 7,105 m/z values, which were obtained by a
binning procedure from ~350,000 m/z values in the
raw data.
It is worthwhile to point out that these data sets are
preprocessed by different methods. In fact, we conducted
baseline correction, smoothing, normalization, and peak
alignment for the Ovarian-qaqc data. The baseline for
each profile was estimated within multiple shifted win-
dows of widths 200 m/z, and the spline approximation
was employed to predict the baseline. The mass spectra
were further smoothed using the ‘lowess’ method, and
normalized by standardizing the area under the curve
(AUC) to the group median [26]. Alternatively, we only
conducted the baseline correction, normalization and
smoothing for the HCC and Cirrhosis, HCC and ToxPath
data (The smoothing method is selected as a different
‘least-square polynomial’ algorithm) [25,26]. We did not
conduct our own preprocessing for the Colorectal data
because it was preprocessed data [17]. Table 1 sketches
the basic information about the five mass spectra data.
The state-of-the-art comparison algorithms in proteomic
diagnosis
We compare our DCA-SVM based profile biomarker
diagnosis with following state-of-the-arts in this work.
They include a partial least square (PLS) based linear
logistic discriminant analysis (PLS-LLD) [27,28], standard
SVM [21], a SVM combining with principal component
analysis: PCA-SVM [8], and a SVM with input-space fea-
ture selection: fs-SVM.
These comparison classifiers can be categorized into
three groups, i.e., The group 1 only consists of standard
SVM itself; The group 2 consists of those classifiers
integrating SVM with input space and subspace feature
selection methods respectively, i.e., PCA-SVM and fs-
SVM; The group 3 consists of a non-SVM classifier,
which employs partial least square (PLS) to conduct
dimension reduction for linear logistic discriminant ana-
lysis [27,28]. The reason we select PLS-LLD classifier is
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that it generally outperforms the other similar non-SVM
(e.g., PCA-LDA) methods according to our implementa-
tions and Sampson et al ‘s work [29].
It is noted that we employ two different input-space
methods: t-test and anona1 (one-way ANOVA) in fs-SVM
to conduct feature selection for binary and multi-class
data respectively [30]. Since serum proteomics data usually
follow or approximately follow a normal distribution after
normalization, it is reasonable to use a two-sample t-test
to rank each feature under a binary case. For multi-class
data such as Cirrhosis and Toxpath, we use one-way
ANOVA (anova1) to identify its statistically significant fea-
tures [30]. As such, we select a feature set including all
features with p-values < 0.05 under the t-test and anova1
for each data. Moreover, since the PLS-LLD classifier
involved matrix inverse calculation, which is notorious for
its high computing demand for a large matrix (e.g., a 5,000
× 5,000 matrix), we only pick 2000 top-ranked features
from for this method to avoid large computing overhead.
Kernel selection, cross validation, and parameter setting
It is noted that we employ the ’linear’ kernel
k(x, y) = (x • y) in all SVM-related classifiers for its effi-
ciency in omics data classification, rather than nonlinear
kernels (e.g., Gaussian kernels). In our previous work, we
actually have pointed out that nonlinear kernels (e.g., Gaus-
sian kernels) would lead to overfitting for gene expression
and proteomics data [6,8]. Although Gaussian kernels are
quite popular in serum proteomics diagnosis, it would give
deceptive diagnosis due to overfitting [6]. In fact, we will
show serum proteomics data diagnosis is a linear separable
problem, for which a linear kernel should be the optimal
kernel selection in next section.
To avoid potential biases from presetting training/test
data partition on classification, we employ the k-fold
(k = 5) cross-validation in our experiments to evaluate
the five classifiers’ performance for all data sets instead of
the independent test set approach. In the 5-fold cross-
validation, proteomic samples are randomly partitioned
into k = 5 folds equally, k = 4 folds are used as training
data each time, the fold left is used for evaluation. Such a
process is repeated k = 5 times. In addition to choosing
the first ten PLS components in the PLS-LLD classifier,
we uniformly set the transform level J = 7; cutoff τ = 2;
and apply the first loading vector based detail coefficient
matrix reconstruction in DCA for all data sets for the
convenience of comparison, though these parameter set-
ting may not be optimal.
Diagnostic performance measures
Before we demonstrate our profile biomarker approach’s
advantages. We introduce several key diagnosis perfor-
mance measures, which are diagnostic accuracy, sensi-
tivity, specificity and positive predication ratios, as
follows. The diagnostic accuracy is the ratio of the cor-
rectly classified test samples over total test samples. The
sensitivity, specificity, and positive predication ratio are
defined as the rates TP/(TP+FN), TN/(TN+FP), and TP/
(FP+TP) respectively, where TP (TN) is the number of
positive (negative) targets (a positive (negative) target is
a proteomic sample with ‘+1’ (’-1’) label) correctly diag-
nosed and FP (FN) is the number of negative (positive)
targets incorrectly diagnosed by the classifier (e.g.,
SVM). It is noted that the sensitivity, specificity, and
positive predication ratio for multiclass data Cirrhosis
and Toxpath are obtained by treating them as a corre-
sponding binary data. For instance, we group 78 HCC
and 51 cirrhosis samples into a same class type.
Figure 3 compares the DCA-SVM’s average diagnosis
and its standard deviations with those of the comparison
algorithms. We have found that proposed DCA-SVM
achieves a nearly rivaling-clinical level diagnosis and
demonstrates strongly leading advantages over its peers
in a stable manner. Alternatively, those comparison
algorithms seem to show quite large level oscillations
that indicate that the classifiers lack stability and good
generalization capacities across different data sets, which
probably exclude themselves as candidates for clinical
proteomics diagnosis.
For example, DCA-SVM achieves 99.52% (sensitivity:
100%, specificity: 99.17%), 100% (sensitivity: 100%, specifi-
city: 100%), and 99.44% (sensitivity: 98.00%, specificity:
100%) diagnostic accuracies on the Ovarian-qaqc, Colorec-
tal and HCC data respectively. However, the SVM classi-
fier only attains corresponding 97.68% (sensitivity: 96.78%,
specificity: 98.40%), 96.48% (sensitivity: 96.92%, specificity:
95.78%), 87.93% (sensitivity: 90.32%, specificity: 85.62%)
diagnostic accuracies respectively for these three data sets.
Such a consistently leading performance is highlighted
further in multiclass phenotype diagnosis. Our DCA-
SVM algorithm reaches 97.50%, 99.01% diagnostic rates
for Toxpath and Cirrhosis data respectively. However,
the SVM classifier can only achieve 75.80% and 88.06%
diagnosis for the same data sets respectively.
Although the input-space or subspace methods may
boost diagnosis sometimes for binary-type data set (e.g.,
for HCC data PCA-SVM, fs-SVM attains 93.56% and
Table 1 Benchmark proteomic data
Data #Feature #Sample Platform
Cirrhosis 23846 72 controls +
78 HCCs +
51 cirrhosis
MALDI-TOF
Colorectal 16331 48 controls + 64 cancers MALDI-TOF
HCC 6107 181 controls +176 cancers SELDI-QqTOF
Ovarian-qaqc 15000 95 controls + 121 cancers SELDI-TOF
ToxPath 7105 28 normals +
43 potential normals +
34 cardiotoxicities +
10 potential cardiotoxicities
SELDI-QqTOF
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90.18% diagnosis which are higher than the 87.93% diag-
nostic ration from the SVM classifier), they seem not be
able to increase a SVM classifier’s diagnosis and genera-
tion abilities significantly, especially for multiclass data.
For instance, the fs-SVM and PCA-SVM both have
lower or the same level diagnosis than the original SVM
without feature selection on Toxpath and Cirrhosis data.
This may suggest the selected features’ unpredictable
impacts on serum proteomics diagnosis due to the input
and subspace feature selection methods’ limitations in
de-noising and latent data characteristics capturing.
In contrast to the proposed DCA-SVM algorithm, all
the comparison algorithms including PLS-LLD, which
achieves slightly better diagnosis than SVM, PCA-SVM,
and fs-SVM, shows high-level oscillations in diagnosis
like the others, across different data. It is noteworthy
that the high-level oscillations in diagnosis is further
highlighted by corresponding large standard deviation
values in diagnosis from those classifiers in Figure 3,
where DCA-SVM demonstrates its good stability and
generalization for its smallest standard deviation values
across all the data sets.
We have to point out that such an excellent perfor-
mance is because DCA forces the SVM hyperplane con-
struction to rely on the both latent and global data
characteristics in a de-noised feature space under a lin-
ear kernel, which contributes to a robust and consistent
high-accuracy diagnosis. Such consistent performance
applies all five data sets, which prevents from any possi-
ble overfitting possibility. On the other hand, just as we
pointed out in our previous work, overfitting always
happens on nonlinear kernels (e.g., Gaussian kernels) in
omics data classification [6,8].
A potential solution to overcome the data reproducibility
Figure 4 compares the performance of five classifiers
across four data sets under k-fold (k = 5) cross validation
in terms of diagnostic accuracy, sensitivity, specificity and
positive predication ratios. It seems that DCA-SVM has
attained strong advantages over its peers in terms of diag-
nostic measures. In fact, all classifiers except DCA-SVM
Figure 3 Comparing DCA-SVM based profile-biomarker diagnosis’ average diagnostic accuracies and its standard deviations with
those of other peers.
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show relatively high-level oscillations for these diagnostic
measures. For example, fs-SVM achieves 96.48% diagno-
sis for the Colorectal data but only 70.47% for the Tox-
path data. To further demonstrate DCA’superiority in
serum proteomics data diagnosis, we compare DCA-
SVM results with those previous results obtained for
these data sets in the literature as follows.
For Colorectal data, a 97.5% diagnosis accuracy with sen-
sitivity 98.4% and specificity 95.8% were attained under
5-fold cross-validation in [17], where a wavelet transform is
directly applied to each proteomic sample by applying
Kolmogorov-Smirnov (KS) and Mann-Whitney (MW)
tests to the wavelet coefficients before calling a standard
SVM classifier [30]. However, our DCA-SVM achieves
100% diagnosis accuracy with sensitivity 100% and specifi-
city 100%. It is worthwhile to point out that our compari-
son algorithms: fs-SVM and PLS-LLD have attained
96.48% (sensitivity: 96.92%, specificity: 95.78%), and 97.31%
(sensitivity: 96.00%, specificity: 98.46%) diagnosis accuracies
with very general feature selection under 5-fold CV ([14]
uses a double CV consisting of 5-fold CV and leave-one-
out CV).
For HCC data, a ~90%+ diagnosis accuracy with sensi-
tivity 91% and specificity 92% is achieved by a particle
swarm optimization based support vector machines (PSO-
SVM) with baseline selection under a 10-fold cross-valida-
tion [23]. Instead, our DCA-SVM achieves 99.44% diagno-
sis accuracy (sensitivity: 99.44%, specificity: 99.44%) under
5-fold CV. In fact, all comparison algorithms expect SVM
achieves same or high level performance than the previous
PSO-SVM approach.
For Ovarian-qaqc data, our DCA-SVM achieves a
99.53% clinical-level diagnosis accuracy with sensitivity
98.95% and specificity 100%, which is better than the
original diagnosis level obtained in [23] and all the other
peers; For Cirrhosis data, Ressom et al partitioned this
three-class data into two binary data sets and proposed
a novel hybrid ant colony optimization based support
vector machines (ACO-SVM) to achieve 94% and 100%
specificity to distinguish hepatocellular carcinoma
(HCC) from Cirrhosis [24]. There was no result available
to distinguish normal, HCC, and cirrhosis in a multi-
class diagnostic way. However, our proposed DCA-SVM
has achieved 99.01% diagnosis accuracy for this multi-
class data sets; The DCA-SVM achieves a rivaling clini-
cal diagnosis accuracy 97.5% for the Toxpath data,
which is a subset of the original data with 203 samples
in [25] (we remove the 88 samples whose class-type is
‘unknown’ to avoid ambiguity in diagnosis).
It is noted that those algorithms applied to these data
sets are generally individualized methods designed for a
specific proteomics data. However, our proposed deriva-
tive component analysis based classifier (DCA-SVM) can
apply to all data sets generated from different experi-
ments and profiling technologies with rival-clinical diag-
nosis. Moreover, since DCA outputs a same-dimensional
meta-data for each input proteomics data, it seems to be
able to provide a potential profile-biomarker approach to
overcome the data reproducibility issue by viewing the
meta data as a uniform profile-biomarker by employing
DCA-SVM to achieve rivaling-clinical diagnosis. To
some degree, DCA and DCA-SVM show some promising
Figure 4 Comparing profile-biomarker diagnosis’ diagnostic accuracies, sensitivity, specificity, and positive predication ratio with
those of other peers across four proteomics data under 5-fold cross validation.
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to use a profile-biomarker way to resolve such a problem
for its latent data characteristics extraction and excep-
tional diagnosis.
Serum proteomics data are linearly separable
Our DCA-SVM algorithm’s rivaling clinical level perfor-
mance may suggest that serum proteomic data classifi-
cation can be a linearly separable problem under
appropriate feature selection. Such a proposition would
provide a direct theoretical support to clarify some
doubts about the nonlinearity in serum proteomics data
may prevent it from complex disease diagnosis clinical
routine [3,5,17], and suggest feasibility to conduct dis-
ease phenotype discrimination by using few biomarkers.
In other words, if serum proteomics data are linearly
separable, then, using biomarker patterns can guarantee
disease phenotype discrimination, which is a key in early
cancer discovery. Otherwise, seeking biomarker patterns
only have a partial meaning if serum proteomics data
are linearly non-separable or nonlinear because these
biomarkers cannot attain 100% or rival clinical (e.g.,
99%) disease phenotype separation. Moreover, serum
proteomics data are linearly separable indicates ‘linear ’
kernels rather than nonlinear ones would be optimal
one for SVM in disease diagnosis. We sketch the defini-
tion of a linear separable problem as follows.
Linearly separable problem
A linearly separable problem can be simply described as
follows. Given P = [x1, x2, · · · xN]T , Q = [y1, y2, · · · yM]T ,
i = 1, 2, · · ·N, i = 1, 2, · · ·N, j = 1, 2, · · ·M, if there exists
a hyperplane H: wTv + b = 0, w, v,∈ n, b ∈ , such that
∀y ∈ Q, ∀y ∈ Q, wTx + b > 0 and wTy + b < 0, then P
and Q are linearly separable data, i.e. classifying P and
Q is a linearly separable problem. In other words, it is
equivalent to mapping entries in P and Q to two differ-
ent types of labels (e.g., +1 and -1) respectively. Such a
definition can be extended similarly to more than two
sets, e.g., P1; P2...Pm, m ≥ 2, which is equivalent to map-
ping the m sets to the labels 1,2,...m respectively.
It’s clear to see that binary and multiclass SVMs by nat-
ure are linear separable test methods for its optimal hyper-
plane construction. However, due to the fact that serum
proteomic profiles are noisy data with redundant informa-
tion, it is rather difficult to draw a conclusion that they are
linearly separable data because of its relatively low classifi-
cation accuracies from most SVM classifier.
However, the DCA-SVM’s exceptional performance
reaches 99.53% 99.44%, 100%, for Ovarian-qaqc, HCC,
and Colorectal, respectively, which strongly demonstrates
they are linearly separable data. Although DCA-SVM only
achieves 97.50% and 99.01% for Toxpath and Cirrhosis
respectively, which are much better than those of the
state-of-the-arts, we still believe the performances indicate
these serum proteomic data are linearly separable,
considering possible factors to lead to small misclassifica-
tions such as complexities of multi-class SVM hyperplane
construction, possible numerical artifacts in SVM algorithm
implementations, and small likelihoods that the SVM deci-
sion function may not provide a deterministic answer [21].
Thus, DCA-SVM disease classification results demonstrate
that these high-dimensional data are actually linearly separ-
able in a de-noised feature space when their latent data
characteristics are extracted by DCA. Alternatively, it
means the linear kernel is the optimal kernel for SVM.
DCA-MRAK: a DCA-induced biomarker discovery
Motivated by DCA-SVM’s exceptional performance, we
present a DCA-induced biomarker discovery algorithm:
DCA-MARK to further validate the linear separability of
serum proteomics data, where each biomarker can be
viewed as a statistically significant feature with respect
to the others [30]. That is, we demonstrate a serum pro-
teomic data set ‘s linear separability by employing the
few biomarkers discovered from its meta data obtained
from DCA. We will demonstrate that these biomarkers
from DCA-MARK can easily separate disease phenotype
completely for high-dimensional proteomics data. To
the best of our knowledge, there is no similar result
available in the previous research. The DCA-MARK can
be sketched as follows.
1). Given an input dataset X ∈ n×p, we seek the bio-
markers by looking at its meta data X∗ from DCA
through scoring and ranking each feature in X∗ by using
the t-statistic for the binary data and F-statistic for the
multiclass data [30].
2). Given a feature in a binary-class dataset
x = x1 · · · xn1+1 · · · yn1+n2 in X∗, the t-statistic is calculated
as t = |x − y|/
√
s2x /n1 + s2y /n2,where x, y, s
2
x , s
2
y are the mean
and variance values of the two classes of entries in the
feature x. In practice, we can employ the pooled variance
estimation to calculate a same variance for two types of
entries as s2p = ((n1 − 1)s2x + (n2 − 1)s2y )/(n1 + n2 − 2).
3). Given a feature in a multi-class dataset with
k > 2 classes, the F-statistic is calculated as
F =
∑k
j=1
nj/(x∗j − x∗)
2
/(k − 1)/
∑k
j=1
(nj − 1)s2j /(nT − k)), where nj
is the sample size, parameters x∗j and s2j are the sample
mean and sample variance for the j-th class.
x∗ =
∑k
j=1
∑nj
i=1 x
∗
ij/nT is the overall sample mean where x
∗
ij
is the expression value of i-th observation for the class j
and nT =
∑T
j=1 nj is the total sample size for the k groups.
4). The biomarkers are the top-ranked features with
the largest statistic values or the smallest p-values, i.e.
we pick the three top-scored biomarkers for the sake of
3-dimensional visualization convenience.
Figure 5 illustrates the separation of four benchmark
data sets with three top-ranked biomarkers (peaks) from
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DCA-MARK. It is interesting to see that these high-
dimensional proteomic profiles can be separated almost
completely with few biomarkers identified from DCA-
MARK. We can also obtain meaningful biological depth
by checking these biomarkers. For example, the SW plot
in Figure 5 shows the separation of 176 controls and
181 cancers in the HCC data, which is generated by
high resolution mass spectral SELDI-Qq-TOF platform,
by the top-ranked biomarkers (peaks) at 2534.2, 2584.3,
and 6486.2 m/z ratios, where each dot represents a sam-
ple (a patient with HCC or a healthy subject). It is clear
that we achieve linear separability for this data by using
only three biomarkers. It is also interesting to see that
two biomarkers are from downstream m/z ratios, which
were believed to be more sensitive to detect phenotype
information than those from upstream m/z ratios [24].
Such a separation actual fits to the linearly separable
case for an SVM classifier. Thus, it is quite easy to iden-
tify a hyperplane to separate two classes phenotypes
completely. For example, we run SVM for the three bio-
markers for the total 357 samples and achieve 100%
classification accuracy (sensitivity: 100%, specificity:
100%). Such a result demonstrates a strong advantages
in phenotype discrimination over the previous work
[17,23,24], just as we pointed out before, which
employed quite complicate evolutionary algorithm
(PSO-SVM) to collect a set of informative peaks and
achieved 90%+ diagnosis accuracy under a 5-fold cross
validation [23].
Moreover, we select three top-ranked biomarkers at
1668.99, 5907.73, 5907.13 m/z ratios for the Cirrhosis
dataset, which is a three-class high-resolution MALDI-
TOF proteomic profile with 23,846 features [24]. In
addition to demonstrating the linear separability, the
phenotype separations provided by the three biomarkers
give very meaningful biological information. The SE plot
in Figure 5 shows the three clearly separable clusters,
where Cirrhosis cluster with 51 samples (blue) have clo-
ser spatial distances to the HCC cluster 78 samples
(red) than the normal cluster with 72 samples (yellow).
Such spatial distances demonstrated by our biomarkers
are actually consistent to their pathological distances:
Cirrhosis is the middle stage to hepatocellular carci-
noma (HCC) for a healthy subject [31]. To the best of
our knowledge, no previous work achieved the similar
results.
Figure 5 Separating disease phenotypes of four serum proteomic data sets by only using their three biomarkers with the smallest
p-values.
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Discussion
In this study, we propose a novel feature selection algo-
rithm: derivative component analysis (DCA) to over-
come the weakness of the traditional feature selection
methods. Unlike the traditional methods, the DCA
focuses on latent data characteristics gleaning and de-
noising by analyzing derivative data components for
input data to calculate a same dimensional meta-data.
We further embed derivative component analysis into
support vector machines to achieve rivaling clinical level
phenotype discrimination for five benchmark serum
proteomics data by comparing it with the other state-of-
the-arts. The DCA-SVM ‘s exceptional classification
accuracies suggest the serum proteomics data’s linear
separability and further inspire DCA-MARK, a DCA-
induced biomarker discovery approach, which in turn
demonstrate high-dimensional proteomics data ‘s linear
separability with few biomarkers. Moreover, derivative
component analysis (DCA) demonstrate a potential to
resolve data reproducibility problem of serum proteo-
mics by viewing each input data’s meta-data as a profile
biomarker by employing DCA-SVM to achieve clinical
level disease diagnosis, because of DCA’s true signal
extraction for input proteomics data.
Such profile biomarker diagnosis approach actually
demonstrates strong advantages over the existing bio-
marker discovery oriented diagnosis by treating input
proteomic data as a profile biomarker. The systems
approach seems to fit the “personalized diagnostics” bet-
ter [32], because it can be difficult both biologically and
computationally to achieve a clinical level diagnostics
for those complex diseases like cancer, in which thou-
sands genes can be involved, based on several differen-
tially expressed proteins, especially when the source data
suffer from the reproducibility issue.
Our experimental results demonstrated that the DCA’s
parametric tuning works efficiently though they may not
be the optimal ones theoretically. It is possible to seek
optimally parametric settings in derivative component
analysis for each proteomic data from an information
entropy analysis or Monte Carlo simulation standing
point [18]. However, we are not sure such computing
demand way is practically worthwhile because the clini-
cal level diagnostics are already attained under our cur-
rent parametric tuning.
Conclusions
Our DCA provides an alternative feature selection by
implicitly extracting useful data characteristics whiling
maintaining the data ‘s original dimensionality. It sug-
gests that subtle data characteristics gleaning and de-
noising may be more important in proteomics data fea-
ture selection and following phenotype discrimination. It
is worthwhile to point out that DCA-related techniques
developed can be also applied to gene expression data
smoothly. Although we are quite optimistic to see that
our DCA-MARK can capture meaningful peaks from
low-weight sera from different data sets, there is still an
urgent need to verify and compare these biomarkers
with the previous ones to seek potential pathological
meaning and clinical application. Although derivative
component analysis does show a potential to conquer
the reproducibility problem of serum proteomics, a
future concrete proteomics clinical test is still needed to
explore such a potential. Although we are quite optimis-
tic to see that our DCA-SVM based diagnosis will be a
potential candidate to achieve a clinical disease diagnosis
in proteomics by conquering the reproducibility pro-
blem, rigorous proteomics clinical tests are needed
urgently to explore such a potential and validate its clin-
ical effectiveness. In our ongoing work, we are working
with pathologists to investigate extending the profile-
biomarker diagnosis approach to TCGA and RNA-Seq
data besides genes expression array analysis [33,34].
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